The global small cell lung cancer (SCLC) therapeutics industry was valued at US$ 4.6 billion in 2022. The market is anticipated to expand at a CAGR of 11.9% from 2023 to 2031 and is projected to reach more than US$ 12.9 billion by 2031. Rising incidence of lung cancer, increasing awareness regarding early cancer diagnosis, and growing advancements in precision medicine are driving market growth...